Meeting Banner
Abstract #4777

Target performance of MRI-ultrasound fusion guided prostate biopsy in a cohort of patients suspicious for prostate cancer

Matthias Gergely Zadory1, Jean-Luc Fehr2, Claudius Moeckel2, Seife Hailemariam3, Johannes Malte Froehlich1, and Michael Patak4

1Pharmaceutical sciences institute, ETHZ, Zurich, Switzerland, 2Zentrum für Urologie, Hirslanden Klinik, Zurich, Zurich, Switzerland, 3Institut für histologische und zytologische Diagnostik, Aarau, Switzerland, 4Radiologie, Hirslanden Klinik, Zurich, Zurich, Switzerland

Conventional systematic core biopsies might fail to detect clinical significant prostate cancer. ARTEMIS MRI-ultrasound fusion guided prostate biopsy (ART-PBx) might overcome this issue by improving the targeting of suspicious lesions. In a retrospective clinical study including 194 patients (243 lesions) we determined a target performance of 56.3 % positive biopsies related to histopathology. The detection rate rises up to 71.4% for high score lesions (PIRADS 5) but did not show any correlation with lesion’s size. This target methodology based on MRI achieves greater detection rate of clinical significant prostate cancer, improving the ability to appropriately counsel patients regarding therapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here